Research chemicalPsychedelicSubstituted amphetamineDOx amphetamine
DOBU
Also known as 2,5-dimethoxy-4-butylamphetamine
DOBU (2,5-dimethoxy-4-butylamphetamine) is a longer alkyl-chain member of the DOx amphetamine psychedelics. Shulgin found it markedly weaker than shorter-chain analogues like DOM, and it remains extremely obscure.
01 Overview
DOBU extends the 4-alkyl chain of the DOx series to n-butyl. Increasing chain length beyond a few carbons sharply reduces 5-HT2A potency, and Shulgin reported only weak activity at high doses. It is essentially never encountered recreationally.
Despite low potency, the DOx-class caveats of long duration and vasoconstriction still apply, and no safety data exist.
02 Mechanism
5-HT2A partial agonist; the bulky 4-n-butyl group reduces receptor affinity relative to DOM/DOB, lowering potency.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Reported active | 10–25 mg | Oral | Shulgin range; effects described as weak, long duration. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Weak psychedeliaFaint perceptual and cognitive changes reported at high doses. | mild | Anecdotal | |
| Mild stimulationLow-level amphetamine-like arousal. | mild | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| VasoconstrictionDOx-class peripheral vasoconstriction with cold extremities. | Moderate | Common | Anecdotal | |
| Prolonged durationLike other DOx compounds, effects and any adverse reaction persist for many hours. | Moderate | Common | Anecdotal |
06 Legal status
United Kingdom
Psychoactive Substances Act 2016
as of Jan 2026
United States
Schedule I (Federal Analogue Act)
Analogue when intended for consumption. · as of Jan 2026
07 References
PiHKAL: A Chemical Love Story (DOBU entry)Shulgin & Shulgin, 1991
08 Discussion0 comments
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.